Gelesis picks up $64.3 mln
Gelesis, a biotechnology company focused on treating chronic diseases related to the gastrointestinal tract, has secured $64.3 million in funding.
Gelesis, a biotechnology company focused on treating chronic diseases related to the gastrointestinal tract, has secured $64.3 million in funding.
Copyright PEI Media
Not for publication, email or dissemination